Zhejiang Huahai Pharmaceutical Co., Ltd.

Boehringer Ingelheim GmbH ’s IL-36 inhibitor Spevigo has impressed in a pivotal trial for generalized pustular psoriasis (GPP) flare prevention with plans in place for regulatory filings later this ye

The Medicines Patent Pool was on to a good thing when it signed a licensing agreement with Pfizer for nirmatrelvir while it was still an investigational COVID-19 antiviral treatment candidate PF-073

Citing prices that authorities described as "too high," Beijing has refused to grant insurance coverage to the most sought-after drug in China beyond 31 March, despite surging COVID-19 infections foll

The Medicines Patent Pool (MPP) was on to a good thing when it signed a licensing agreement with Pfizer Inc. for nirmatrelvir while it was still an investigational COVID-19 antiviral treatment candi